SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as discussions swirl around potential partnerships with rivals like AMD and Apple for its foundry business, fueled by reports and government initiatives to bolster domestic chip manufacturing. Community members debate the implications of these partnerships, potential for revenue growth, and impact on Intel's valuation, with some expressing optimism about a turnaround driven by government support and AI advancements. Others caution about execution risks and the need for concrete results to justify the stock's recent gains.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is generating buzz as the community rallies to get it trending, emphasizing its active development team and engaged community. Discussions highlight the coin's utilities, ongoing contests, and upcoming staking features, positioning it as more than just another meme coin in the Solana ecosystem. Some users have also expressed excitement for 'Uptober'.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending due to positive sentiment around its potential in the weight loss and diabetes drug market, fueled by a new facility announcement and promising trial data for its oral GLP-1.  The community is actively discussing its competitive positioning against Novo Nordisk and speculating on potential acquisitions in the sector. Some investors are also considering the impact of potential government actions, such as tariffs and direct consumer pricing initiatives.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as chatter revolves around a potential collaboration with Intel as a foundry customer, sparking debate about its impact and the competitive landscape with TSMC and Samsung. Community members are actively discussing the news' validity, potential benefits, and AMD's overall valuation amidst the ever-evolving semiconductor sector. Technical analysis and price target speculation are also contributing to the heightened interest in the stock.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is experiencing volatility, with community discussions focusing on a potential link to ChatGPT's reduced reliance on Reddit data, impacting its AI narrative and prompting a sharp sell-off. Dip buyers are active, while others point to strong institutional ownership and upcoming earnings as reasons for optimism, despite concerns around political bias on the platform. Some traders are also drawing parallels between RDDT and RUM, noting potential political catalysts and high short interest in RUM.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DKNG is trending downwards amidst concerns that prediction markets, like Kalshi and Robinhood, are gaining traction and posing a competitive threat. The community is actively discussing the potential impact on DraftKings' market share and revenue, with some criticizing the company's leadership for not adapting quickly enough. Investors are also monitoring broader industry trends, including regulatory developments and the potential for increased competition.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to significant volatility following earnings, with community debate centered on the company's future growth and valuation. A short report from Fuzzy Panda is adding to the uncertainty, while bulls point to raised ARR guidance and potential short squeeze setups. The stock's price action and high trading volume are attracting attention as investors digest conflicting viewpoints.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid social media discussions spurred by Elon Musk's call to cancel subscriptions, citing concerns over content aimed at children and related controversies. The community is debating the impact of these sentiments on the stock's value, while some defend Netflix, pointing to its strong fundamentals and subscriber base. Technical analysis suggests key support and resistance levels are being closely watched as the stock navigates market sentiment.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending as discussions revolve around potential catalysts including a deal with TrumpRx and investment in US manufacturing, which could boost the stock. The community is weighing the impact of these developments on Pfizer's valuation, noting institutional buying and potential for future growth in areas like weight-loss drugs. Some investors believe that the stock is undervalued and anticipate a significant rise.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors digest recent earnings and future guidance, with community members weighing the potential for short-term gains amidst broader discussions of memory market cycles. Despite strong financial results and tailwinds from increased data center spending and AI, some traders are expressing caution, citing overbought conditions and potential pullbacks. Community talking points include discussions around potential squeeze plays, price targets, and the impact of broader market trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of immunomodulation required for Sarepta Therapeutics' gene therapy (SRPT) Elevidys.The FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy (DMD) patients on Elevidys, Citi said, as per TheFly. Siromilus belongs to a group of medicines known as immunosuppressive agents and has shown promise in managing certain aspects of liver disease and its complications.Citi has a ‘Sell’ rating and a $14 price target on <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> shares. On Stocktwits, retail sentiment around Sarepta fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:563/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_2_11_08_PM_png_5b28899976.webp" alt="SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>Citi made the observations in light of the FDA’s recommendations for Rocket Pharmaceuticals (RCKT) made public earlier in the day.Rocket <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> earlier on Wednesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said.The agency allowed the trial to resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing and with an immunomodulatory regimen more closely reflecting the one administered in an early-stage study pediatric cohort.Sarepta, like Rocket Pharma, has been plagued by patient deaths. It's gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.SRPT stock is down by 83% this year and by about 86% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 

Equity

Rocket Pharmaceuticals, Inc. (RCKT) on Wednesday said that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease.The hold, <a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-downgraded-after-patient-death-but-retail-bullish/ch0oee8RbrA">imposed</a> roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold">said</a>. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.Rocket Pharma stock shot up 25% in Wednesday’s pre-market session following the development. On Stocktwits, retail sentiment around RCKT rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from 'low' to 'normal' levels.&nbsp;Danon disease is a rare, genetic disorder primarily affecting the heart, skeletal muscles, and sometimes the brain. It's characterized by weakening of the heart muscle, muscle weakness, and intellectual disability.Following the death of a patient, Rocket paused further dosing in the mid-stage study, and on May 23, the FDA placed a clinical hold on the trial to allow for further evaluation. The trial can now resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing, followed by additional patients to complete the trial. The low dose has been determined as most likely to confer the safety and efficacy identified in the low-dose early-stage study cohorts, the company said.Rocket also said that it will collaborate with investigators to implement an immunomodulatory regimen more closely reflecting the one administered in the early-stage study pediatric cohort. Further updates about the mid-stage study can be expected following review of data from the next three patients, the company said.RCKT stock is down by 77% this year and by about 85% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Rocket Pharma Stock Up 25% Pre-Market Today? 

The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.

RCKT Stock Tanks on Patient Death in Danon Disease Study

Wall Street analysts issued a fresh round of ratings changes on Wednesday, including notable upgrades for State Street (STT) and FICO (FICO) and downgrades for Booz Allen (BAH) and Rocket Pharmaceuticals (RCKT), according to TheFly.Top 3 Upgrades:State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85. The brokerage sees the company as the biggest beneficiary among trust banks from the recent equity market rebound.<a href="https://stocktwits.com/symbol/STT">State Street’s stock</a> was up 0.71% in morning trade on Wednesday.JPMorgan upgraded Vail Resorts’ (MTN) shares to ‘Neutral’ from ‘Underweight,’ keeping the $167 target, citing improved risk-reward at current levels.&nbsp;The upgrade comes after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/vail-resorts-brings-back-longtime-ceo-rob-katz/ch0odyHRbrF">announced</a> on Tuesday that Rob Katz will return as CEO, effective immediately, replacing Kirsten Lynch, who has served as chief executive for three years.<a href="https://stocktwits.com/symbol/MTN">Vail Resorts’ stock</a> rocketed 14.44% in morning trade on Wednesday.Baird shifted its outlook on FICO’s shares to a more bullish stance, raising the stock to ‘Outperform’ from ‘Neutral’ but with a lower price target of $1,900, down from $2,021. The brokerage said the stock’s recent sell-off, tied to regulatory risk, creates upside potential.<a href="https://stocktwits.com/symbol/FICO">Fico’s stock</a> traded up 6.3%&nbsp;on Wednesday morning.Top 3 Downgrades:Goldman Sachs cut its&nbsp;rating on Booz Allen’s stock to ‘Sell’ from ‘Neutral,’ trimming the price target to $94 from $108, citing limited medium-term growth and downside valuation risk.<a href="https://stocktwits.com/symbol/BAH">Booz Allen’s stock</a> fell 2.24% in morning trade on Wednesday.Meanwhile, TD Cowen downgraded Freshpet (FRPT) shares to ‘Hold’ from ‘Buy’, maintaining a price target of $96. The brokerage said slowing retail sales growth triggered the call.<a href="https://stocktwits.com/symbol/FRPT">Freshpet’s stock</a> was down 4.18%&nbsp;on Wednesday morning.&nbsp;Jefferies slashed its rating on Rocket Pharmaceuticals stock to ‘Hold’ from ‘Buy’ and the price target to $2.50 from $29, citing an FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-downgraded-after-patient-death-but-retail-bullish/ch0oee8RbrA">clinical hold</a> on a key gene therapy trial.&nbsp;<a href="https://stocktwits.com/symbol/RCKT">Rocket Pharmaceutical’s</a> stock was up 3.6% at the start of Wednesday’s session despite the bearish outlook.The broader market traded in the red as investors watched for Nvidia’s (NVDA) earnings after the closing bell. The SPDR&nbsp;<a href="https://stocktwits.com/symbol/SPY">S&amp;P 500</a> ETF Trust (SPY) fell 0.14%, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ</a> Trust (QQQ), which tracks the Nasdaq 100, edged 0.04% lower. The SPDR&nbsp;<a href="https://stocktwits.com/symbol/DIA">Dow Jones Industrial Average</a> ETF (DIA) was down 0.1%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/game-stop-stock-climbs-after-first-ever-bitcoin-buy-worth-half-a-billion/ch0oSz2RbsX">GameStop Stock Declines After First-Ever Bitcoin Buy Worth Half A Billion</a>

The Wall Street Bull statue in Manhattan. (Photo by Erik McGregor/LightRocket via Getty Images)

Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today

State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85.

Rocket Pharmaceuticals (RCKT) plunged nearly 63% on Tuesday, hitting an all-time low after the U.S. FDA placed a clinical hold on its gene therapy trial, RP-A501, for Danon disease following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-pauses-rocket-pharmaceuticals-gene-therapy-trial-after-patient-death/ch0V9xRRbrR">death</a> of a patient.The selloff marked the company's worst session on record.&nbsp;Despite the steep decline, retail investor sentiment remained notably bullish. Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers&nbsp;over the past 24 hours — the highest among healthcare stocks on Tuesday.<h3>Wall Street Turns Cautious</h3>According to The Fly, the incident prompted a wave of downgrades from major analysts:<ul style="list-style-type:circle;"><li>Morgan Stanley cut RCKT to 'Equal Weight' from 'Overweight' and slashed its price target from $42 to $7, which still implies more than 200% upside from current levels.</li><li>Leerink lowered its rating to 'Market Perform' from 'Outperform' with a new target of $8. The firm cited three overhangs: safety concerns, shaken investor confidence, and financial pressure.</li><li>TD Cowen downgraded the stock to 'Hold' from 'Buy,' citing unresolved safety risks related to thrombotic microangiopathies that preceded the addition of the C3 inhibitor.</li><li>Needham also moved to 'Hold' from 'Buy' and withdrew its $42 target, calling RP-A501 the company's "main value driver" but now fraught with uncertainty.</li></ul><h3>Retail Shrugs Off Worries</h3>Despite the institutional pullback, retail traders doubled down. Stocktwits sentiment turned 'extremely bullish,' with many users arguing that Rocket's broader pipeline remains compelling.<figure class="image"><img style="aspect-ratio:1322/862;" src="https://news.stocktwits-cdn.com/RCKT_chart_with_sentiment_meter_and_message_volume_as_of_May_27_png_0e99f740f3.webp" alt="RCKT chart with sentiment meter and message volume as of May 27.png" width="1322" height="862"><figcaption>RCKT chart with sentiment meter and message volume as of May 27. | source: Stocktwits</figcaption></figure>One optimist expects the stock to be "back over $4.50 (maybe $5) within 3 months."<stembedurl>https://stocktwits.com/srick2000/message/615977188</stembedurl>"For one moment, ignore the CV gene therapy, which is the cause of today's drop, and just look at the rest of the pipeline here. Particularly late-stage hematology," posted another, citing the firm's leadership, including CCO &amp; CMO Sarbani Chaudhuri, formerly with Johnson &amp; Johnson.<stembedurl>https://stocktwits.com/geegor/message/615978028</stembedurl>RCKT shares gained about 3% in after-hours trading following the plunge in the regular session.The episode echoes a March setback for&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-therapeutics-stock-has-a-nightmarish-week-after-dmd-patient-death/ch78AvoRbPU">Sarepta Therapeutics</a> (SRPT), when a patient receiving its approved Duchenne muscular dystrophy therapy died from liver failure.&nbsp;As Barron's&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barrons.com/articles/gene-therapy-trial-death-rocket-stock-7aee984c?mod=md_stockoverview_news">noted</a>, such high-profile incidents have made gene therapy stocks increasingly unpalatable for many investors, despite the field's early promise.<a href="https://stocktwits.com/symbol/RCKT">Rocket Pharma shares</a> are now down over 80% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trader watching stocks crash on screen - stock photo. 

Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery

Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers.

Shares of Rocket Pharmaceuticals, Inc. (RCKT) traded 64% lower in Tuesday’s pre-market trading session after the U.S. Food and Drug Administration (FDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-provides-update-phase-2-clinical-trial-rp">placed</a> a clinical hold on its trial related to investigational gene therapy for Danon disease called RP-A501, following the death of a patient.The patient was part of the Phase 2 trial of RP-A501. They experienced an unexpected Serious Adverse Event (SAE) involving clinical complications related to a capillary leak syndrome (CLS), which led to their passing.CLS is a condition where fluid and proteins leak out of the small blood vessels and into surrounding tissues, causing dangerously low blood pressure, fluid buildup in the body, and other complications.Rocket Pharma said it is conducting a comprehensive root cause analysis and is in active dialogue with the FDA.While the company voluntarily paused dosing in the study after the death of the patient, the FDA on May 23 also placed a clinical hold on the trial to allow further evaluation, the company said.Rocket Pharmaceuticals said that it is working with the FDA to ensure the safety of all study patients and resume the trial “as expeditiously as possible,” but stopped short of providing a timeline for the resumption of trials.The company also said that it expects its existing resources to be sufficient to fund operations into 2027. Rocket had cash, cash equivalents, and investments of $318.2 million at the end of the first quarter.On Stocktwits, retail sentiment around Rocket Pharmaceuticals jumped from ‘bearish’ to ‘extremely bullish’ territory while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_27_at_8_29_26_AM_png_8a7c609af6.webp" alt="RCKT's Sentiment Meter and Message Volume as of 8:30 a.m. ET on May 27, 2025 | Source: Stocktwits" width="626" height="65"><figcaption>RCKT's Sentiment Meter and Message Volume as of 8:30 a.m. ET on May 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the drop in share price over the news could result in a strong entry point.<stembedurl>https://stocktwits.com/TheCatalystCalendar/message/615894941</stembedurl><a href="https://stocktwits.com/symbol/RCKT">RCKT stock</a> is down by over 50% this year and more than 70% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/sanofi-vnvc-open-vaccine-manufacturing-in-vietnam/ch0VBtPRbrb">Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish

Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible."

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Rocket Pharmaceuticals Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$3.20
Prev Close	$3.26
Open	$3.24
Dividend Yield	0.00%
50-Day Moving Average	$3.20
Beta	1.14
Avg. Volume	5.8M
PE Ratio	-1.30

52-Week High	$18.89
52-Week Low	$2.19
Market Capitalization	$351.77M
EPS (Annual)	-$2.73
Price to Book	0.99
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

RCKT
Rocket Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RCKT News

RCKT Rocket Pharmaceuticals Inc